

Life feels good.

Founded
1968

Location
Castellbisbal, Barcelona, Spain

Main Focus
CNS, Nephrology, Urology, Cardiovascular, Gastroenterology, Rheumatology/Orthopedic, Oncology/Radiotherapy, Gynecology.

About Rubiό

For more than 55 years Rubiό, a family-owned company, has been recognized for the development, manufacture and marketing of medicines with high therapeutic value for specialists as well as of certain drugs for life-threatening diseases, with long expertise in niche markets.

Rubiό's determination to meet the health needs of every single patient has led the company to be distinguished as per being pioneer of products targeted to low incidence diseases which affect only a small number of patients and that require the development of specific pharmaceutical products to treat them.

International Alliances and Partnering Strategy

Rubiό has established a strong network of partnerships through in and out activities and commercial distribution agreements. Rubiό has been in the export business since 1982 and has alliances in over 70 countries. Rubiό is constantly exploring new territories and partnerships.

Contact details:

Laboratorios Rubiό, S.A.
Industria 29, P.I. Comte de Sert
08755 Castellbisbal, Barcelona, Spain
Tel.: +34 937 722 509
www.laboratoriosrubiō.com

Contact:
export@labrubiō.com

Sodium Polystyrene Sulfonate

Effective and safe treatment in the management of Hyperkalaemia



General Information

Name:	Resinsodio®
API:	Sodium Polystyrene Sulphonate
Presentation:	400 g multi-dose plastic bottle with a measuring spoon that holds approx. 5 g of powder
Pharmaceutical form:	Powder for oral/rectal suspension

Indications

- Treatment and prevention of hyperkalaemia in adults and children.

Competitives Advantages

- Resinsodio® has showed efficacy in the reduction of potassium.
- Sugar free.
- Non-systemic absorption.
- Low cost in daily treatment.
- For patients with hypercalcemia.

Clinical Studies

- Clinical bibliographical data available for the active ingredient.

Registration and Marketing Authorization

- Bibliographical dossier available (well-established medicinal use).
- Resinsodio® marketed in Spain since 1968. To be registered as well established medicinal use. The originator is Kayexalate® / Resonium-A®. Sodium polystyrene sulphonate is an insoluble, locally acting, with no systemic absorption substance. The bioequivalence study is not a suitable way to show therapeutic equivalence for this type of products. Bridging to data on formulations described in literature should be justified based on qualitative and quantitative composition. In some particular cases, an "in vitro" study of Resinsodio® against the originator or the reference product in the country is required.
- Marketed in CL, CU, CY, FR, ML, NL, SG, TH, TT & UY.
- Under registration process in HK & GR.

Deal Design

- We are looking for partners having a relevant sales structure in Nephrology, specially oriented to Hospitals, Clinics, Dialysis Centres and Nephrologists.
- Deal design consisting of a License & Supply and/or Distribution Agreement to market the Finished Product manufactured by Laboratorios Rubiό, S.A.
- We are searching for the best Partners to develop trustful, fruitful and long term business partnerships.